



Stefan Diem

contact

first name	Stefan
last name	Diem
country	Switzerland
e-mail	stefan.diem@kssg.ch

publications

title

journal paper/ review

Berner F, Bomze D, Diem S, Ali O H, Fässler M, Ring S, Niederer R, Ackermann C J, Baumgaertner P, Pikor N, Gil Cruz C, van de Veen W, Akdis M, Nikolaev S, Läubli H, Zippelius A, Hartmann F, Cheng H W, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy A N, Jochum W, Speiser D E, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. *JAMA Oncol* 2019;.

Diem S, Fässler M, Bomze D, Ali O H, Berner F, Niederer R, Hillmann D, Mangana J, Levesque M P, Dummer R, Risch L, Recher M, Risch M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. *J Immunother* 2019; 42:89-93.

Schmid S, Diem S, Li Q, Krapf M, Flatz L, Leschka S, Desbiolles L, Klingbiel D, Jochum W, Früh M. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). *Cancer Immunol Immunother* 2018;.

Safroneeva E, Saner C, Rossel J B, Golay D, Pittet V, Godat S, Diem S, Aepli P, Sauter R, Borovicka J, Burgmann K, Juillerat P, Netzer P, Sendensky A, Hruz P, Girardin M, Biedermann L, Greuter T, Vavricka S, Michetti P, Mueller C, Straumann A, Schoepfer A M, Swiss EoE Cohort Study Group . Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECs). *Inflamm Intest Dis* 2018; 2:163-170.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A J, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. *Lung Cancer* 2017; 111:176-181.

publications

title

**journal
paper/
review**

Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French L E, Speiser D E, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. *Oncoimmunology* 2016; 5:e1231292.

Diem S, Kasenda B, Spain L, Martin-Liberal J, Marconcini R, Gore M, Larkin J. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. *Br J Cancer* 2016; 114:256-61.

Diem S, Keller F, Rüesch R, Maillard S A, Speiser D E, Dummer R, Siano M, Urner-Bloch U, Goldinger S M, Flatz L, Diem S. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. *J Immunother* 2016; 39:379-382.

Hasan Ali O, Diem S, Aschwanden J, Markert E, Tasman A J, Müller J, Flatz L. GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography. *JAAD Case Rep* 2016; 2:415-417.

Diem S, Ess S, cerny t, Früh M, Hitz F. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. *Eur J Intern Med* 2014; 25:577-82.

Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thürlimann B, cerny t. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. *Eur J Clin Pharmacol* 2014; 70:719-25.



projects

title	status
Immunmonitoring of patients before, during and after immunotherapy to predict anti-tumor response in melanoma and non-small cell lung cancer (IMIT)	ongoing - recruiting phase



projects

title	status
A Multicenter Phase III Randomized study with second line chemotherapy plus or minus Bevacizumab in patients with Plati-num sensitive Epithelial ovarian cancer recurrence after a Bevacizumab/chemotherapy first line	automat- ically closed



projects

title	status
A Phase I and stratified, multicenter Phase II trial of transdermal CR1447 (4-OH-testosterone) in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer	automatically closed
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with KRAS- and BRAF wild-type metastatic colorectal cancer. A multicenter phase II trial, Leit-EK Zürich	aborted